Teva Pharmaceutical Industries (MEX:TEVA N) 3-Month Share Buyback Ratio : -1.16% (As of Mar. 2025 )

View and export this data going back to 2011. Start your Free Trial

What is Teva Pharmaceutical Industries 3-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Teva Pharmaceutical Industries's current 3-Month Share Buyback Ratio was -1.16%.

Competitive Comparison of Teva Pharmaceutical Industries's 3-Month Share Buyback Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Teva Pharmaceutical Industries's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Teva Pharmaceutical Industries's 3-Month Share Buyback Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Teva Pharmaceutical Industries's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Teva Pharmaceutical Industries's 3-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Teva Pharmaceutical Industries 3-Month Share Buyback Ratio Calculation

Teva Pharmaceutical Industries's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2025 is calculated as

3-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Dec. 2024 )	-	Shares Outstanding (EOP) (Mar. 2025 ))	/	Shares Outstanding (EOP) (Dec. 2024 )
	=	(1133.839	-	1146.960)	/	1133.839
	=	-1.16%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Teva Pharmaceutical Industries (MEX:TEVA N) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Teva Pharmaceutical Industries 3-Month Share Buyback Ratio Related Terms

Teva Pharmaceutical Industries Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Teva Pharmaceutical Industries Ltd (MEX:TEVA N) » Definitions » 3-Month Share Buyback Ratio

Traded in Other Exchanges

TEVJF:USA TEVA:USA TEVA:Israel 0LER:UK TEV:Germany TEV:Germany T1EV34:Brazil TEV:Bulgaria TEVA:Austria

Address

124 Dvora HaNevi’a Street, Tel Aviv, ISR, 6944020

Website

https://www.tevapharm.com

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Teva Pharmaceutical Industries Headlines

No Headlines